| Drug Name |
Lomustine |
| Drug ID |
BADD_D01313 |
| Description |
An alkylating agent of value against both hematologic malignancies and solid tumors. |
| Indications and Usage |
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease. |
| Marketing Status |
Prescription |
| ATC Code |
L01AD02 |
| DrugBank ID |
DB01206
|
| KEGG ID |
D00363
|
| MeSH ID |
D008130
|
| PubChem ID |
3950
|
| TTD Drug ID |
D04JPJ
|
| NDC Product Code |
43744-331; 58181-3042; 71052-171; 55111-965; 58181-3041; 58181-3040; 72969-040 |
| Synonyms |
Lomustine | NSC-79037 | NSC 79037 | NSC79037 | Cecenu | CeeNU | Belustine | CCNU |
